Patents by Inventor Edwin J Schweiger

Edwin J Schweiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9000022
    Abstract: Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: April 7, 2015
    Assignee: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • Publication number: 20140038964
    Abstract: Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
    Type: Application
    Filed: July 25, 2013
    Publication date: February 6, 2014
    Applicant: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin J. Schweiger, William C. Stevens, JR., Tie-Lin Wang, Yinong Xie
  • Patent number: 8013001
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Haixia Wang, Yinong Xie
  • Publication number: 20100056582
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 17, 2008
    Publication date: March 4, 2010
    Applicant: X-CEPTOR THERAPEUTICS, INC.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, JR., Haixia Wang, Yinong Xie
  • Patent number: 7482366
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: July 24, 2004
    Date of Patent: January 27, 2009
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Christopher D Bayne, Alan T Johnson, Shao-Po Lu, Raju Mohan, Michael C Nyman, Edwin J Schweiger, William C Stevens, Jr., Haixia Wang, Yinong Xie
  • Publication number: 20080132521
    Abstract: Compounds of formula (I): wherein n, R1, R2, R3 and R7 are disclosed herein, are useful in treating disease-states associated with nuclear receptor activity. Pharmaceutical compositions comprising and methods of using said compounds are also disclosed herein.
    Type: Application
    Filed: July 27, 2007
    Publication date: June 5, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Alan T. Johnson, Satoru Kaneko, Raju Mohan, Kozo Oda, Edwin J. Schweiger
  • Publication number: 20080119488
    Abstract: Compounds of the invention, such as compounds of formula (I), where n, m, A, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: July 24, 2005
    Publication date: May 22, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, Haixia Wang, Yinong Xie, Lynne Canne Bannen, Diva Sze-Ming Chan, Ping Huang, Vasu Jammalamadaka, Richard G. Khoury, Morrison B. Mac, Jason Jevious Parks, Yong Wang, Wei Xu
  • Patent number: 7265131
    Abstract: Compounds of formula (I): wherein n, R1, R2, R3 and R7 are disclosed herein, are useful in treating disease-states associated with nuclear receptor activity. Pharmaceutical compositions comprising and methods of using said compounds are also disclosed herein.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: September 4, 2007
    Assignee: Exelixis, Inc.
    Inventors: Alan T Johnson, Satoru Kaneko, Raju Mohan, Kozo Oda, Edwin J Schweiger
  • Publication number: 20040204447
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: December 17, 2003
    Publication date: October 14, 2004
    Applicants: X-Ceptor Therapeutics Inc., Sankyo Company, Limited
    Inventors: Alan T. Johnson, Satoru Kaneko, Raju Mohan, Kozo Oda, Edwin J. Schweiger
  • Publication number: 20030055247
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.
    Type: Application
    Filed: August 13, 2002
    Publication date: March 20, 2003
    Inventors: Nicholas David Peter Cosford, Leo Solomon Bleicher, Jean-Michel Andre Vernier, Rowena V. Cube, Edwin J. Schweiger, Ian McDonald